Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
| Price | $17.12 |
|---|---|
| Market cap | $1.04B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 7.29-28 |
| Beta | 1.45 |
Explore JBIO's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.